Biomarkers Of Lynch syndrome Tumours (BOLT)

• Research type

  Research Study

• Full title

  Biomarkers of Lynch-Syndrome Tumours (BOLT)

• IRAS ID

  195219

• Contact name

  Neil Ryan

• Contact email

  neilryan@nhs.net

• Sponsor organisation

  University of Manchester

• Duration of Study in the UK

  2 years, 8 months, 27 days

• Research summary

  Summary of Research
  This is an exploratory study with the aim of contributing pilot data
  1. Provide the first Micro-RNA profile of Lynch syndrome associated endometrial cancer (womb cancer)
  2. Explore potential biomarkers (unique biological qualities) for Lynch syndrome associated endometrial cancer focusing on proxies, that is markers that can be used to easily identify, for the mechanisms responsible for promoter methylation (which is a process in cells by which genes are 'switched on/off').
  3. Explore the mechanisms responsible for tumourgenesis (cancer formation) in both sporadic and Lynch syndrome associated endometrial cancers.

  Summary of Results
  Through the comparison of womb cancers that arose in women with Lynch syndrome versus women who did not have Lynch syndrome we were able to demonstrate that
  1.) Lynch syndrome associated womb cancers illicit a much stronger immune response than other womb cancers
  2.) Lynch syndrome associated womb cancers come about due to mutations in genes that are not seen in non Lynch syndrome associated womb cancers
  3.) The technology for performing micro-satellite instability testing, as evaluated in 2019, was not accurate in Lynch syndrome associated womb cancers
  4.) Spectroscopy is a promising technology that could be used to diagnose Lynch syndrome associated womb cancers

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  16/NW/0164

• Date of REC Opinion

  12 Apr 2016

• REC opinion

  Further Information Favourable Opinion